RxDoctor Payments Data

Fadi Dahdaleh, MD

Surgical Oncology · Chicago, ILNPI 1235424656

Payments from drug & device makers

What this record shows

This record is dominated by education: $163,800 of the $197,730 with a category attached, or 82.8%. Intuitive Surgical accounts for 98.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $82,187 and has fallen 79.4% since, to $16,904 in 2025. Among surgical oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$197,730in general payments, 2019–2025

Across 202 payments — averaging $978.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$195K
  • Angiodynamics, Inc.$686
  • Medical Device Business Services, Inc.$623
  • Johnson & Johnson$541
  • Conmed Corporation$179
  • Baxter Healthcare$105
  • plus $372 from 10 others

What the payments were for

  • Speaking & faculty fees$18,5009%
  • Travel & lodging$6,0983%
  • Food & beverage$9,3325%
  • Education$163,80083%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$197,730 in reported general payments places this provider in the 95th percentile of 55 surgical oncology providers in Illinois.

See all surgical oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$190,474
Medicare patients
219
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl19$291
Neomycin Sulfate32$173
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$111
Metronidazole32$60
Oxycodone Hcl16$52

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →